GIP/GLP-1 receptor agonistGut microbiotaBile acidsHepatic steatosisTirzepatide mitigates hepatic steatosis in HFD/STZ-induced diabetic mice.Tirzepatide remodeled the gut microbiota and BAs metabolism in HFD/STZ-induced diabetic mice.Tirzepatide emerges as a promising therapeutic candidate for managing ...
The objective of this article is to review the efficacy and safety of tirzepatide and discuss its potential role in the treatment of type 2 diabetes. Tirzepatide is a novel once-weekly dual GIP and GLP-1 receptor agonist which has been studied in the SURPASS clinical trials in doses of ...
The Novel Dual GIP and GLP‐1 Receptor Agonist, Tirzepatide, Transiently Delays Gastric Emptying Similarly to Selective Long‐Acting GLP‐1 Receptor Agonistsantidiabetic drugGIPGLP‐1 analogueincretin therapytype 2 diabetesdoi:10.1111/dom.14110
The IDF Virtual Congress 2023 will be held from December 4 to 7. Phase 1 study data from Hansoh Pharma’s HS-20094 (a novel dual GIP and GLP-1 receptor agonist) will be released at the Congress in the form of posters and oral presentations. This study shows that HS-20094 exhibites go...
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP‐1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose‐escalation Phase I study 优化的GLP-1/GIP受体双重激动剂(BGM0504)在健康志愿者中的安全性、耐受性、药代动力学和药效学:一项剂量递增I期研究...
receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently market...
3.00% (0.86) for the placebo group, with a safety profile consistent with GIP and GLP-1 receptor agonists.38 Key unanswered biological questions which are pertinent to MASH There remains a debate as to whether GLP-1RAs have direct, independent effects on MASH or whether they impact on pathoph...
The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as
The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treati